source
- FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel oppositionFDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients. The approval was issued on Friday even th…
- Akeso and Summit report ivonescimab meets overall survival endpoint in Phase 3 lung cancer trialAkeso and its partner Summit said the Phase 3 trial of ivonescimab, a PD-1xVEGF bispecific antibody, has met its overall survival endpoint in a selected group of lung cancer patients. The announcem…